[Research Advances in Evaluation and Measurement Techniques of Latent Human Immunodeficiency Virus Reservoirs]

Overview

Journal Zhejiang Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2016 Sep 22

PMID 27651189

Authors

Zhou Qihui

Zhu Biao

Affiliations

Soon will be listed here.

Abstract

Latent reservoir (LR) of HIV is the cells (such as CD4(+)T cell) where HIV is able to hide. These cellular reservoirs are located throughout the body, including the spleen, lymph nodes, gastrointestinal lymphoid tissues, and become the major obstacle to cure HIV infection. To truly cure patients, a new strategy "shock and kill" was put forward by scientists, which is to shock HIV-infected cells out of hidden reservoirs in the body and then kill them. Quantitatively evaluating the size of long-lived LR is essential to this strategy. This paper reviews assays that measure the magnitude of the latent HIV reservoir, including Alu-gag PCR, quantitative viral outgrowth assay (Q-VOA) and tat/rev induced limiting dilution assay(TILDA). Alu-gag PCR can differentiate the integrated and un-integrated HIV DNA, however, it cannot distinguish defective virus from competent virus, leading to overestimate the real size of LR. Q-VOA is based on cell culture, and is the golden standard for measuring the LR since it provides a definitive minimal estimate of reservoir size. Its disadvantages are being more costly, large amount of blood sample required, and underestimating the true size, which was resulted from particles being not released after one round of stimulation. TILDA measures cells with inducible msRNA as these transcripts are absent in latently infected cells but induced upon viral reactivation. It requires small blood sample size, does not need extraction of viral nucleic acids, can be completed in 2 d and covers a wide dynamic range of reservoir sizes, but has the disadvantage of overestimating the true size of LR.

References

Pasternak A, Lukashov V, Berkhout B . Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology. 2013; 10:41. PMC: 3637491. DOI: 10.1186/1742-4690-10-41. View

Archin N, Sung J, Garrido C, Soriano-Sarabia N, Margolis D . Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol. 2014; 12(11):750-64. PMC: 4383747. DOI: 10.1038/nrmicro3352. View

Tyagi M, Bukrinsky M . Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med. 2012; 18:1096-108. PMC: 3475336. DOI: 10.2119/molmed.2012.00194. View

Barton K, Palmer S . How to Define the Latent Reservoir: Tools of the Trade. Curr HIV/AIDS Rep. 2016; 13(2):77-84. PMC: 4821866. DOI: 10.1007/s11904-016-0304-1. View

Alidjinou E, Bocket L, Hober D . Quantification of viral DNA during HIV-1 infection: A review of relevant clinical uses and laboratory methods. Pathol Biol (Paris). 2014; 63(1):53-9. DOI: 10.1016/j.patbio.2014.07.007. View

Agosto L, Liszewski M, Mexas A, Graf E, Pace M, Yu J . Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology. 2010; 409(1):46-53. PMC: 3253773. DOI: 10.1016/j.virol.2010.08.024. View

Han Y, Wind-Rotolo M, Yang H, Siliciano J, Siliciano R . Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol. 2007; 5(2):95-106. DOI: 10.1038/nrmicro1580. View

Laird G, Eisele E, Rabi S, Lai J, Chioma S, Blankson J . Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 2013; 9(5):e1003398. PMC: 3667757. DOI: 10.1371/journal.ppat.1003398. View

Pace M, Agosto L, Graf E, ODoherty U . HIV reservoirs and latency models. Virology. 2011; 411(2):344-54. PMC: 3618966. DOI: 10.1016/j.virol.2010.12.041. View

10.

Bruner K, Hosmane N, Siliciano R . Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol. 2015; 23(4):192-203. PMC: 4386620. DOI: 10.1016/j.tim.2015.01.013. View

11.

Rouzioux C, Richman D . How to best measure HIV reservoirs?. Curr Opin HIV AIDS. 2013; 8(3):170-5. PMC: 3763804. DOI: 10.1097/COH.0b013e32835fc619. View

12.

Chun T, Moir S, Fauci A . HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015; 16(6):584-9. DOI: 10.1038/ni.3152. View

13.

Barouch D, Deeks S . Immunologic strategies for HIV-1 remission and eradication. Science. 2014; 345(6193):169-74. PMC: 4096716. DOI: 10.1126/science.1255512. View

14.

ODoherty U, Swiggard W, Jeyakumar D, McGain D, Malim M . A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol. 2002; 76(21):10942-50. PMC: 136638. DOI: 10.1128/jvi.76.21.10942-10950.2002. View

15.

Kiselinova M, De Spiegelaere W, Buzon M, Malatinkova E, Lichterfeld M, Vandekerckhove L . Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathog. 2016; 12(3):e1005472. PMC: 4777389. DOI: 10.1371/journal.ppat.1005472. View

16.

Shan L, Siliciano R . From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays. 2013; 35(6):544-52. PMC: 4386637. DOI: 10.1002/bies.201200170. View

17.

Procopio F, Fromentin R, Kulpa D, Brehm J, Bebin A, Strain M . A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine. 2015; 2(8):874-83. PMC: 4563128. DOI: 10.1016/j.ebiom.2015.06.019. View

18.

Chun T, Carruth L, Finzi D, Shen X, DiGiuseppe J, Taylor H . Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997; 387(6629):183-8. DOI: 10.1038/387183a0. View

19.

Liszewski M, Yu J, ODoherty U . Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods. 2009; 47(4):254-60. PMC: 2862469. DOI: 10.1016/j.ymeth.2009.01.002. View

20.

Dahl V, Josefsson L, Palmer S . HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res. 2009; 85(1):286-94. DOI: 10.1016/j.antiviral.2009.09.016. View